Neurocrine Sets Benchmark For Measuring Health Improvements In Tardive Dyskinesia Patients
Neurocrine Biosciences (NBIX) presented research setting a 6-point increase on the EQ-VAS as a benchmark for meaningful health improvements in tardive dyskinesia patients treated with INGREZZA. The company's Phase 4 KINECT-PRO study showed a 13.1-point average improvement in overall health scores after 24 weeks. The findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference.
How this was made
The 30-second read
Why it matters
The new benchmark provides a quantifiable measure of clinical benefit, potentially supporting pricing, payer discussions, and future trial designs.
Market read
First disclosure of a meaningful improvement metric for INGREZZA, likely to influence NBIX valuation and peer biotech sentiment.
What to watch
Reimbursement negotiations and payer acceptance will ultimately drive commercial impact.
Background
Neurocrine Biosciences (NBIX) presented research establishing a 6‑point EQ‑VAS improvement threshold for patients with tardive dyskinesia treated with INGREZZA.
Ticker impact
Neurocrine disclosed a new 6‑point EQ‑VAS threshold for meaningful improvement with INGREZZA, based on Phase 4 KINECT‑PRO data.
likely modest upside as investors price in stronger clinical support for INGREZZA
First‑time disclosure of a clinically meaningful improvement metric; supports future pricing and reimbursement discussions.
Market effects
May boost confidence in TD therapeutics and could influence peer biotech valuations.
Primarily U.S. biotech market; limited broader regional effect.
Relevant to global investors tracking neuro‑psychiatric drug pipelines.
Counterpoint
If the benchmark is seen as modest, it may not materially change valuation expectations.
Key entities
- companyNeurocrine Biosciences
Developer of INGREZZA for tardive dyskinesia.
- drugINGREZZA (valbenazine)
Approved treatment for tardive dyskinesia.
